gel-e news

October 16, 2017 - gel-e will be presentating at the Q3 Ernerging Medical Technologies (EMT) Spotlight event on Friday Oct 20, 2017

September 13, 2017 - gel-e Expands Core Team with Regulatory, Manufacturing and Financial Talent

gel-e Inc. a privately held, clinical-stage medical device company, announces the recent expansion of its core team, adding Elsa Abruzzo as Head of Regulatory, Bruce Choi as Head of Manufacturing, and Rich Vincent as the CFO.

Supported by its recent financing, the Company has been able to attract an experienced and talented group to support key corporate objectives: expanding gel-e’s initial U.S. FDA regulatory clearance to a broader hemostatic product line for the treatment of external wounds, establishing cGMP manufacturing of gel-e's active ingredient, and preparing for the commercialization of its growing product line.

“Elsa, Bruce and Rich have already started making contributions as part of our expanded gel-e team," said Larry Tiffany, President and Director of gel-e "Elsa has been instrumental in designing and implementing our regulatory strategy in order to expand our label claims for a variety of hemostatic products. Integrated into this strategy, Bruce is leading our core team to establish a manufacturing facility using a modular manufacturing approach that will support scale-up while ensuring we meet our quality, productivity and efficiency goals. Rich helped us close the recent equity round, and brings his expertise from many successful West Coast life science start-ups and commercial companies, including raising $650M in private and public financings, most recently for Genoa Pharmaceuticals." To learn more about each of their backgrounds, please visit our team page.

July 13, 2017 - gel-e Secures $3.1 Million Financing

gel-e Inc., announces that it has raised $3.1 million in a private financing, led by early-stage investment funds and life science investors.

The financing allows gel-e to expand its initial U.S. FDA regulatory clearance for the management of bleeding wounds, including vascular access sites (Vascular gel-e®) to a broader hemostatic product line for the treatment of external wounds. In parallel, this funding allows the company to establish cGMP manufacturing of gel-e's active ingredient. If you'd like to learn more visit

"gel-e exemplifies an ideal investment for us," said Jim Hughes, Director, UM Ventures. "By strategically deploying grants, gel-e has built an impressive corporate foundation, such as achieving its first regulatory clearance, securing an issued patent estate, and recognition through numerous peer-reviewed publications. We are excited to be a part of this financing that supports the next phase in the company's growth."

gel-e's mission is to develop a broad range of game-changing hemostatic and wound treatment products, including bandages for the treatment of routine cuts and scrapes, foams and putties for traumatic and military injuries, and surgical gels and powders. The path created by Vascular gel-e® facilitates expansion of the company's portfolio, while gaining greater confidence about the platform's safety and efficacy for future indications, including internal surgical use.

Prior to this financing, gel-e was funded by grants from the National Science Foundation (through the SBIR), the United States Army Research Lab, Maryland Industrial Partnerships, and the Technology Development Corporation (TEDCO).

"I've had the chance to apply the technology in a few research studies," said Dr. Mayur Narayan, attending trauma surgeon and Associate Program Director of the Surgical Critical Care Fellowship at Weill Cornell Medical College/ New York Presbyterian Hospital. "These studies involved lethal bleeding in large animal models, where we were able to achieve rapid hemostasis using gel-e hemostats with superior results to competitive products."

February 1, 2017 - New Notice of Trademark Allowance

The USPTO issued a notice of trademark allowance on the name "gel-e," which is at the core of our branding. This allowance continues the build of our intellectual property estate, and we believe it to be an important asset moving forward.

See Trademark Serial Number: 87/045,953

January 15, 2017 - Biz Dev deal signed with the Jai Group

The Jai Group (JG) is a West Coast business development firm with a focus on pharmaceutical and medical device partnerships in Latin America. gel-e and JG just inked a deal through which JG will identify the best Latin American partners for gel-e's currently cleared Vascular Access product as well as future products. JG has an excellent track record of obtaining valuable licensing and distribution partnerships in Latin America for their clients.

September 15, 2016 - New Supplemental Grant from the National Science Foundation

gel-e is the recipient of a supplemental grant to our current SBIR Phase II Award from the National Science Foundation for $100,000. The award, called Small-Business / ERC (Engineering Reserach Center) Collaborative Opportunity (SECO), will go towards evaluating the safety of our chitosan-based foam in internal surgical applications. The Company will collaborate with Dr. Steven Stice who works at the Regenerative Engineering and Medicine Research Center, University of Georgia, where the studies will be conducted. This is an exciting development for our internal surgical research program.